Altive | China’s first mRNA COVID-19 vaccine is undergoing Phase III trial

China’s first mRNA COVID-19 vaccine is undergoing Phase III trial

By Altive.21 6月 2021
Share via. 
China’s answer on mRNA to Pfizer

China's first messenger RNA COVID-19 vaccine (ARCoV) is undergoing its Phase III clinical trial, according to China National Radio. The ARCoV vaccine is jointly developed by China's Suzhou Abogen Biosciences, the Institute of Military Medicine under the Academy of Military Sciences and Walvax Biotechnology Co., Ltd.

There are currently two mRNA COVID-19 vaccines that have been approved for use in humans: one developed by U.S. drugmaker Pfizer in partnership with German company BioNTech, and the other by the U.S. National Institute of Allergy and Infectious Diseases together with U.S. biotech firm Moderna Therapeutics.

ARCoV is the first Chinese mRNA vaccine for COVID-19 and it can be stored under 2 to 8°C, hence a much less stringent temperature requirement than shots from western rivals. Abogen is backed by reputable investors including Hillhouse Capital and PICC.

undefined

Source: Reuters & Xinhuanet
Images created by Altive

 Register Account

If you are a Professional Investor and interested in knowing more, please register for an Altive account with us, or login into our portal to access further information.

Discover more of what matters to you
IPO
mRNA
Abogen

Let’s Talk

We look forward to share our insights and information with you.
Language
Connect
@2024 Altive Limited. All rights reserved.
version 1.54.2-prod
This Website and any information contained herein has not been reviewed by Hong Kong Securities and Futures Commission or any other regulatory authority, and is made available by Altive Limited (hereafter “Altive”) for Professional Investors’ general information only and not for any other purpose. For the avoidance of doubt, the term “Professional Investor” refers to and covers Professional Investors as defined under the Securities and Futures Ordinance of Hong Kong, Wholesale Clients within the meaning of the Corporations Act 2001 of Australia, Professional Investors as defined under Securities and Futures Act of Singapore, or other relevant respective local jurisdictions. The Viewer proclaims himself/herself as a Professional Investor by continuing to access the Website. The Viewer agrees that this website shall be used solely as reference, or for informational use and not for any other purposes, commercial or otherwise. Altive is an asset management company licensed with the Securities and Futures Commission (CE no. BPK587) to carry on business in Type 4 (advising on securities) and Type 9 (asset management) regulated activities in Hong Kong under the Securities and Futures Ordinance (Cap. 571). The information contained in this website is not intended and shall not be used or construed as an offer to sell, or a solicitation of any offer to buy, securities of any fund or other investment product in any jurisdiction. The information contained herein is qualified in its entirety by the terms applicable to the investment funds as set out in its constitutive and offering documents (“Fund Documents”) and should be read together with such Fund Documents. Neither Altive nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind related to the adequacy, accuracy or completeness of any information on this site or the use of information on this site. The information in this Website is not intended and should be construed as investment, tax, legal, financial or other advice. Altive holds exclusive and rightful ownership of the intellectual and proprietary rights to all opinions, concepts, ideas, work products, and the like, related to or as a result of the General Information and contents in this Website.